Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease

Karthik D. Nath, Julie G. Burel, Shankar Viswanathan, Antony L. Pritchard, Michelle Towers, David Looke, Janet M. Davies, John W. Upham

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background and objective: Individuals with chronic obstructive pulmonary disease (COPD) are at a high risk of developing signifcant complications from infection with the influenza virus. It is therefore vital to ensure that prophylaxis with the influenza vaccine is effective in COPD. The aim of this study was to assess the immunogenicity of the 2010 trivalent influenza vaccine in persons with COPD compared to healthy subjects without lung disease, and to examine clinical factors associated with the serological response to the vaccine. Methods: In this observational study, 34 subjects (20 COPD, 14 healthy) received the 2010 infu-enza vaccine. Antibody titers at baseline and 28 days post-vaccination were measured using the hemagglutination inhibition assay (HAI) assay. Primary endpoints included seroconversion ($4-fold increase in antibody titers from baseline) and the fold increase in antibody titer after vaccination. Results: Persons with COPD mounted a significantly lower humoral immune response to the infuenza vaccine compared to healthy participants. Seroconversion occurred in 90% of healthy participants, but only in 43% of COPD patients (P=0.036). Increasing age and previous influ-enza vaccination were associated with lower antibody responses. Antibody titers did not vary significantly with cigarette smoking, presence of other comorbid diseases, or COPD severity. Conclusion: The humoral immune response to the 2010 influenza vaccine was lower in persons with COPD compared to non-COPD controls. The antibody response also declined with increasing age and in those with a history of prior vaccination.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalInternational Journal of COPD
Volume9
DOIs
StatePublished - Dec 24 2013

Fingerprint

Humoral Immunity
Chronic Obstructive Pulmonary Disease
Human Influenza
Vaccination
Influenza Vaccines
Healthy Volunteers
Vaccines
Antibodies
Antibody Formation
Obstructive Lung Diseases
Hemagglutination
Orthomyxoviridae
Lung Diseases
Observational Studies
Smoking
Infection

Keywords

  • COPD
  • Human infuenza
  • Humoral immunity
  • Infuenza vaccines

ASJC Scopus subject areas

  • Health Policy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. / Nath, Karthik D.; Burel, Julie G.; Viswanathan, Shankar; Pritchard, Antony L.; Towers, Michelle; Looke, David; Davies, Janet M.; Upham, John W.

In: International Journal of COPD, Vol. 9, 24.12.2013, p. 51-56.

Research output: Contribution to journalArticle

Nath, Karthik D. ; Burel, Julie G. ; Viswanathan, Shankar ; Pritchard, Antony L. ; Towers, Michelle ; Looke, David ; Davies, Janet M. ; Upham, John W. / Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. In: International Journal of COPD. 2013 ; Vol. 9. pp. 51-56.
@article{563404879cc04ead933719941f5453da,
title = "Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease",
abstract = "Background and objective: Individuals with chronic obstructive pulmonary disease (COPD) are at a high risk of developing signifcant complications from infection with the influenza virus. It is therefore vital to ensure that prophylaxis with the influenza vaccine is effective in COPD. The aim of this study was to assess the immunogenicity of the 2010 trivalent influenza vaccine in persons with COPD compared to healthy subjects without lung disease, and to examine clinical factors associated with the serological response to the vaccine. Methods: In this observational study, 34 subjects (20 COPD, 14 healthy) received the 2010 infu-enza vaccine. Antibody titers at baseline and 28 days post-vaccination were measured using the hemagglutination inhibition assay (HAI) assay. Primary endpoints included seroconversion ($4-fold increase in antibody titers from baseline) and the fold increase in antibody titer after vaccination. Results: Persons with COPD mounted a significantly lower humoral immune response to the infuenza vaccine compared to healthy participants. Seroconversion occurred in 90{\%} of healthy participants, but only in 43{\%} of COPD patients (P=0.036). Increasing age and previous influ-enza vaccination were associated with lower antibody responses. Antibody titers did not vary significantly with cigarette smoking, presence of other comorbid diseases, or COPD severity. Conclusion: The humoral immune response to the 2010 influenza vaccine was lower in persons with COPD compared to non-COPD controls. The antibody response also declined with increasing age and in those with a history of prior vaccination.",
keywords = "COPD, Human infuenza, Humoral immunity, Infuenza vaccines",
author = "Nath, {Karthik D.} and Burel, {Julie G.} and Shankar Viswanathan and Pritchard, {Antony L.} and Michelle Towers and David Looke and Davies, {Janet M.} and Upham, {John W.}",
year = "2013",
month = "12",
day = "24",
doi = "10.2147/COPD.S53590",
language = "English (US)",
volume = "9",
pages = "51--56",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease

AU - Nath, Karthik D.

AU - Burel, Julie G.

AU - Viswanathan, Shankar

AU - Pritchard, Antony L.

AU - Towers, Michelle

AU - Looke, David

AU - Davies, Janet M.

AU - Upham, John W.

PY - 2013/12/24

Y1 - 2013/12/24

N2 - Background and objective: Individuals with chronic obstructive pulmonary disease (COPD) are at a high risk of developing signifcant complications from infection with the influenza virus. It is therefore vital to ensure that prophylaxis with the influenza vaccine is effective in COPD. The aim of this study was to assess the immunogenicity of the 2010 trivalent influenza vaccine in persons with COPD compared to healthy subjects without lung disease, and to examine clinical factors associated with the serological response to the vaccine. Methods: In this observational study, 34 subjects (20 COPD, 14 healthy) received the 2010 infu-enza vaccine. Antibody titers at baseline and 28 days post-vaccination were measured using the hemagglutination inhibition assay (HAI) assay. Primary endpoints included seroconversion ($4-fold increase in antibody titers from baseline) and the fold increase in antibody titer after vaccination. Results: Persons with COPD mounted a significantly lower humoral immune response to the infuenza vaccine compared to healthy participants. Seroconversion occurred in 90% of healthy participants, but only in 43% of COPD patients (P=0.036). Increasing age and previous influ-enza vaccination were associated with lower antibody responses. Antibody titers did not vary significantly with cigarette smoking, presence of other comorbid diseases, or COPD severity. Conclusion: The humoral immune response to the 2010 influenza vaccine was lower in persons with COPD compared to non-COPD controls. The antibody response also declined with increasing age and in those with a history of prior vaccination.

AB - Background and objective: Individuals with chronic obstructive pulmonary disease (COPD) are at a high risk of developing signifcant complications from infection with the influenza virus. It is therefore vital to ensure that prophylaxis with the influenza vaccine is effective in COPD. The aim of this study was to assess the immunogenicity of the 2010 trivalent influenza vaccine in persons with COPD compared to healthy subjects without lung disease, and to examine clinical factors associated with the serological response to the vaccine. Methods: In this observational study, 34 subjects (20 COPD, 14 healthy) received the 2010 infu-enza vaccine. Antibody titers at baseline and 28 days post-vaccination were measured using the hemagglutination inhibition assay (HAI) assay. Primary endpoints included seroconversion ($4-fold increase in antibody titers from baseline) and the fold increase in antibody titer after vaccination. Results: Persons with COPD mounted a significantly lower humoral immune response to the infuenza vaccine compared to healthy participants. Seroconversion occurred in 90% of healthy participants, but only in 43% of COPD patients (P=0.036). Increasing age and previous influ-enza vaccination were associated with lower antibody responses. Antibody titers did not vary significantly with cigarette smoking, presence of other comorbid diseases, or COPD severity. Conclusion: The humoral immune response to the 2010 influenza vaccine was lower in persons with COPD compared to non-COPD controls. The antibody response also declined with increasing age and in those with a history of prior vaccination.

KW - COPD

KW - Human infuenza

KW - Humoral immunity

KW - Infuenza vaccines

UR - http://www.scopus.com/inward/record.url?scp=84891390764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891390764&partnerID=8YFLogxK

U2 - 10.2147/COPD.S53590

DO - 10.2147/COPD.S53590

M3 - Article

C2 - 24399872

AN - SCOPUS:84891390764

VL - 9

SP - 51

EP - 56

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -